Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.81 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | RBP4 | P02753 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2509836 | 1.00 | HTR2C (0.81) | HTR2CCHRNB2CHRNA4NOTUMSLC6A2 | |
| SCHEMBL2509837 | 1.00 | HTR2C (0.81) | HTR2CCHRNB2CHRNA4NOTUMSLC6A2 | |
| Hydrochloric Acid SCHEMBL2394649 | 0.98 | HTR2C (0.81) | HTR2CCHRNB2CHRNA4NOTUMSLC6A2 | |
| Hydrochloric Acid SCHEMBL2513159 | 0.98 | HTR2C (0.81) | HTR2CCHRNB2CHRNA4NOTUMSLC6A2 | |
| SCHEMBL16455234 | 0.90 | HTR2C (0.66) | HTR2CCHRNB2CHRNA4HTR1ARBP4 | |
| SCHEMBL30228461 | 0.89 | HTR2C (1.00) | HTR2CCHRNB2CHRNA4SLC6A2SLC6A4 | |
| SCHEMBL613612 | 0.89 | HTR2C (1.00) | HTR2CCHRNB2CHRNA4SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL16446229 | 0.89 | HTR2C (0.67) | HTR2CCHRNB2CHRNA4HTR1ARBP4 | |
| Hydrochloric Acid SCHEMBL30853595 | 0.88 | HTR2C (1.00) | HTR2CCHRNB2CHRNA4SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL307161 | 0.88 | HTR2C (1.00) | HTR2CCHRNB2CHRNA4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245223-A1 | HETEROCYCLIC COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2011-10-06 | — | — | US | claimed |
| EP-1889842-A1 | HETEROCYCLIC COMPOUND | Japan Tobacco, Inc. (JP) | 2008-02-20 | — | — | EP | claimed |
| US-20070072908-A1 | Heterocyclic compounds | JAPAN TOBACCO INC. (JP) | 2007-03-29 | — | — | US | claimed |
| EP-2566859-B1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO LTD (KR) | 2016-12-21 | — | — | EP | disclosed |
| US-9096571-B2 | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-08-04 | — | — | US | disclosed |
| CN-103025721-B | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | SK CHEMICALS CO LTD | 2015-06-17 | — | — | CN | disclosed |
| US-20130210811-A1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO., LTD. (KR) | 2013-08-15 | — | — | US | disclosed |
| CN-103025721-A | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | SK CHEMICALS CO LTD | 2013-04-03 | — | — | CN | disclosed |
| EP-2566859-A2 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Sk Chemicals Co., Ltd. (KR) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011139107-A2 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO.,LTD. (KR) | 2011-11-10 | — | — | WO | disclosed |
| US-20110245223-A1 | HETEROCYCLIC COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20100010219-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100010219-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100010219-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| EP-2103603-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | Japan Tobacco Inc. (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-2103603-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | Japan Tobacco Inc. (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-1889842-A1 | HETEROCYCLIC COMPOUND | Japan Tobacco, Inc. (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20070072908-A1 | Heterocyclic compounds | JAPAN TOBACCO INC. (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245223-A1 | HETEROCYCLIC COMPOUNDS | HSD11B1, HSD11B2, CYP11B1 | HTR2C 1450/4885CHRNB2 3710/4885CHRNA4 3551/4885 |
| US-20130210811-A1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | HSD11B1, HSD11B2, G6PC1 | HTR2C 2472/4885CHRNB2 4656/4885CHRNA4 4523/4885 |
| US-20070072908-A1 | Heterocyclic compounds | HSD11B1, HSD11B2, CYP11B1 | HTR2C 1450/4885CHRNB2 3710/4885CHRNA4 3551/4885 |
| US-20100010219-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | HSD11B1, HSD11B2, HSD17B11 | HTR2C 3041/4885CHRNB2 4728/4885CHRNA4 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.